- Feb 14, 2020
- 1,630
- Tinnitus Since
- 1-2019
- Cause of Tinnitus
- 20+ Years of Live Music, Motorcycles, and Power Tools
I think @Zugzug's mention of it being a "sham" is a better way to look at it. In July 2020, when they took that $42MM private placement, they noted that the ARHL and Severe Phase 1B trials were intended to gain "additional insights regarding the patient populations and severity of hearing loss that FX-322 may treat."So the age-related hearing loss trial was a failure too...
Unfortunately, that insight points to ARHL as not a patient population that FX-322 is able to treat.
Fortunately, this excludes patients with ARHL from being included in any future trials, creating non-responders in treatment groups.
Source:
Frequency Therapeutics Announces $42 Million Private Placement
To me, it's good to see they're narrowing down the populations that FX-322 won't help, so the trials can better focus on the patient population that will show the best response to the drug. The population of people with hearing loss is MASSIVE, and the potential for multiple / varying underlying causes is pretty apparent. So, from a strategic perspective, even if it drug does only treat a class of patients with specifically SNHL Moderate-Severe, that is still a market in the MILLIONS.
Their goal is to get this thing to product. We all have potential access to it, even if we're not the primary candidate, it may provide some relief / healing.
Side note:
When was the last time a biotech company focusing on hearing loss had this many trials active / completed in a 4-year timeframe?